LUMASIRAN SODIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lumasiran sodium and what is the scope of patent protection?
Lumasiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lumasiran sodium has one hundred and seventy-four patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for LUMASIRAN SODIUM
International Patents: | 174 |
US Patents: | 14 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | LUMASIRAN SODIUM at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMASIRAN SODIUM
Generic Entry Date for LUMASIRAN SODIUM*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for LUMASIRAN SODIUM
US Patents and Regulatory Information for LUMASIRAN SODIUM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Alnylam Pharms Inc | OXLUMO | lumasiran sodium | SOLUTION;SUBCUTANEOUS | 214103-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUMASIRAN SODIUM
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Dominican Republic | P2017000094 | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN HAO1 (HIDROXIÁCIDO-OXIDASA 1 (GLICOLATO-OXIDASA)) | ⤷ Subscribe |
Cyprus | 1125364 | ⤷ Subscribe | |
European Patent Office | 3186377 | AGENTS D'ARN DOUBLE BRIN MODIFIÉ (MODIFIED DOUBLE-STRANDED RNA AGENTS) | ⤷ Subscribe |
Japan | 2017002082 | 標的化脂質 (TARGETED LIPID) | ⤷ Subscribe |
Jordan | P20200115 | تركيبات وطرق لتثبيط التعبير الجيني عن HAO1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) (Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression) | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2016028649 | ⤷ Subscribe | |
European Patent Office | 4321177 | CONJUGUÉS GLUCIDIQUES UTILISÉS COMME AGENTS D'ADMINISTRATION POUR DES OLIGONUCLÉOTIDES (CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMASIRAN SODIUM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3581654 | 2021038 | Norway | ⤷ Subscribe | PRODUCT NAME: LUMASIRAN; REG. NO/DATE: EU/1/20/1496 20201124 |
3204015 | 2022C/509 | Belgium | ⤷ Subscribe | PRODUCT NAME: LUMASIRAN, INCLUSIEF ZOUTEN ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1496 20201123 |
3204015 | PA2022004 | Lithuania | ⤷ Subscribe | PRODUCT NAME: LUMASIRANAS; REGISTRATION NO/DATE: EU/120/1496 20201119 |
3581654 | 122021000053 | Germany | ⤷ Subscribe | PRODUCT NAME: LUMASIRAN; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
3581654 | PA2021008,C3581654 | Lithuania | ⤷ Subscribe | PRODUCT NAME: LUMASIRANAS; REGISTRATION NO/DATE: EU/1/20/1496 20201119 |
3204015 | 22C1016 | France | ⤷ Subscribe | PRODUCT NAME: LUMASIRAN, OPTIONNELLEMENT SOUS FORME DE SEL; NAT. REGISTRATION NO/DATE: EU/1/20/1496 20201123; FIRST REGISTRATION: - EU/1/20/1496 20201123 |
3204015 | 2022009 | Norway | ⤷ Subscribe | PRODUCT NAME: LUMASIRAN, OPTIONALLY IN THE FORM OF A SALT; REG. NO/DATE: EU/1/20/1496 20201124 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
LUMASIRAN SODIUM Market Analysis and Financial Projection Experimental
More… ↓